A clinical analysis and literature review of eleven cases with primary pulmonary angiosarcoma by Tao Luan, Jianqing Hao, Yingying Gu, Ping He, Yijia Li, Liqiang Wang, Haiyi Deng, Wenhui Guan, Xinqing Lin, Xiaohong Xie, Yu Deng, Shuaiying Wang, Changchun Wang, Jingxu Li, Ru Li, Yang Luan, Gang Yang, Yunhui Zhang, Nanshan Zhong, Chengzhi Zhou

“…Conclusion Primary pulmonary angiosarcoma is a rare, highly aggressive vascular malignancy characterized by nonspecific clinical symptoms and a tendency for metastasis and pulmonary artery embolism. Currently, no effective treatment exists, and the overall prognosis is poor.…”
Get full text

Characteristics and clinical significance of immune cells in omental milky spots of patients with gastric cancer by Yasunobu Mano, Yasunobu Mano, Yuka Igarashi, Yuka Igarashi, Keisuke Komori, Keisuke Komori, Itaru Hashimoto, Itaru Hashimoto, Hayato Watanabe, Kosuke Takahashi, Kazuki Kano, Hirohito Fujikawa, Takanobu Yamada, Hidetomo Himuro, Hidetomo Himuro, Taku Kouro, Taku Kouro, Feifei Wei, Feifei Wei, Kayoko Tsuji, Kayoko Tsuji, Shun Horaguchi, Shun Horaguchi, Shun Horaguchi, Mitsuru Komahashi, Mitsuru Komahashi, Mitsuru Komahashi, Takashi Oshima, Tetsuro Sasada, Tetsuro Sasada

“…The omentum is a common site of peritoneal metastasis in various cancers, including gastric cancer. …”
Get full text

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan by Eisaku Miyauchi, MD, PhD, Makoto Nishio, MD, PhD, Kadoaki Ohashi, MD, PhD, Atsushi Osoegawa, MD, PhD, Eiki Kikuchi, MD, PhD, Hideharu Kimura, MD, PhD, Yasushi Goto, MD, PhD, Junichi Shimizu, MD, PhD, Hiroshige Yoshioka, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Nobuyuki Katakami, MD, PhD, Masahide Oki, MD, PhD, Takashi Kijima, MD, PhD, Kenichi Chikamori, MD, PhD, Kazumi Nishino, MD, PhD, Yuki Kobayashi, MS, Asako Miwa, BA, Misa Tanaka, MS, Akihiko Gemma, PhD

“…Results: Overall, 403 patients were included; the median age was 71 years, 16.6% (n = 67) had an Eastern Cooperative Oncology Group performance status 2 or more, 26.8% (n = 108) had brain metastasis, 6.9% (n = 28) had interstitial lung disease, 4.0% (n = 16) had autoimmune disease, and 72.7% (n = 293) were IMpower133-unlike. …”
Get full text

Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract by Mohammad Jad Moussa, Georges C. Tabet, Arlene O. Siefker‐Radtke, Lianchun Xiao, Nathaniel R. Wilson, Jianjun Gao, Christopher J. Logothetis, Petros Grivas, Byron Lee, Amishi Y. Shah, Pavlos Msaouel, Roger Li, Leticia Campos Clemente, Jianping Zhao, Nizar M. Tannir, Ashish M. Kamat, Donna E. Hansel, Charles C. Guo, Matthew T. Campbell, Omar Alhalabi

“…The incidence of brain metastasis is notably higher than in “traditional” urothelial cancer within the first year after surgery, especially if small cell cancer persists, thus necessitating close neurological monitoring during this period.…”
Get full text

FAM210B activates STAT1/IRF9/IFIT3 axis by upregulating IFN-α/β expression to impede the progression of lung adenocarcinoma by Xuejuan Gao, Donglan Huang, Ying Liu, Gui Zhang, Xiaofen Zheng, Baiye Guan, Aiwen Chen, Jiayao Wu, Shi-Ming Luo, Zonghua Liu, Luxuan Chen, Xiaohui Liu, Jingjie Jin, Xingfeng Yin, Zhenghua Sun, Yunfang Zhang, Meizhi Lu, Gong Zhang, Wanting Liu, Langxia Liu

“…Accordingly, in vitro and in vivo studies have confirmed the inhibitory role of FAM210B on the growth and tumor metastasis of LUAD cells. RNA-seq analysis further indicated that FAM210B plays a role in regulating innate immune-related signaling pathways in LUAD cells, particularly involving the production of type I interferon (IFN-α/β). …”
Get full text

Comparison of outcome and toxicity of postoperative intensity‐modulated radiation therapy with two‐dimensional radiotherapy in patients with soft tissue sarcoma of extremities and... by Jianyang Wang, Yongwen Song, Xinfan Liu, Jing Jin, Weihu Wang, Zihao Yu, Yueping Liu, Ning Li, Hui Fang, Hua Ren, Yuan Tang, Yu Tang, Bo Chen, Ningning Lu, Shunan Qi, Shulian Wang, Yexiong Li

“…Compared to 2D‐RT group, the IMRT group had higher 5‐year local recurrence‐free survival (LRFS) (91.1% vs 80.8%; P = 0.029), distant metastasis‐free survival (DMFS) (80.0% vs 69.7%; P = 0.048), disease‐free survival (DFS) (75.2% vs 59.2%; P = 0.021), and overall survival (OS) (90.2% vs 81.0%; P = 0.029). …”
Get full text

Reduced p63 expression is linked to unfavourable prognosis in muscle‐invasive urothelial carcinoma of the bladder by Kira Furlano, Henning Plage, Sebastian Hofbauer, Sarah Weinberger, Bernhard Ralla, Annika Fendler, Florian Roßner, Simon Schallenberg, Sefer Elezkurtaj, Martina Kluth, Maximilian Lennartz, Niclas C. Blessin, Andreas H. Marx, Henrik Samtleben, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek, Thorsten Ecke, Stefan Koch, Nico Adamini, Sarah Minner, Ronald Simon, Guido Sauter, Joachim Weischenfeldt, Tobias Klatte, Thorsten Schlomm, David Horst, Henrik Zecha

“…Within 1018 pT2‐4 carcinomas treated by cystectomy, low p63 expression was linked to nodal metastasis (p = 0.0028) and overall survival (p = 0.0005). …”
Get full text

Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR by Pui Yeng Lam, Natacha Omer, Josh K. M. Wong, Cui Tu, Louisa Alim, Gustavo R. Rossi, Maria Victorova, Hannah Tompkins, Cheng‐Yu Lin, Ahmed M. Mehdi, Amos Choo, Melissa R. Elliott, Elaina Coleborn, Jane Sun, Timothy Mercer, Orazio Vittorio, Lachlan J. Dobson, Alexander D. McLellan, Andrew Brooks, Zewen Kelvin Tuong, Seth W. Cheetham, Wayne Nicholls, Fernando Souza‐Fonseca‐Guimaraes

“…These cancers share common challenges, including high rates of metastasis, recurrence or treatment resistance, leading to a 5‐year survival rate of approximately 20% for patients with advanced disease stages. …”
Get full text

ALDH1L2 drives HCC progression through TAM polarization by Jiajun Li, Chi Zhang, Qingqing Zhou, Qinqin Long, Jiayi Chen, Lili Meng, Wei Tian, Yue Yang, Chao Ge, Yuting Su, Xi-Dai Long, Jun Wu, Hua Tian

“…ALDH1L2 promotes tumor cell proliferation and metastasis by activating NRF2/IL-6/STAT3 signaling. …”
Get full text

Clinical and genetic drivers of oligo-metastatic disease in colon cancer by Alessandro Ottaiano, Mariachiara Santorsola, Roberto Sirica, Annabella Di Mauro, Antonella Di Carlo, Monica Ianniello, Francesco Sabbatino, Rosa Castiello, Francesca Del Peschio, Marco Cascella, Francesco Perri, Maurizio Capuozzo, Nicola Martucci, Edoardo Mercadante, Valentina Borzillo, Rossella Di Franco, Francesco Izzo, Vincenza Granata, Carmine Picone, Antonella Petrillo, Massimiliano Berretta, Salvatore Stilo, Luca Tarotto, Anna Chiara Carratù, Gerardo Ferrara, Madhura Tathode, Alessia Maria Cossu, Marco Bocchetti, Michele Caraglia, Guglielmo Nasti, Giovanni Savarese

“…Overall survival (OS) was determined from metastasis diagnosis until death using Kaplan–Meier analysis. …”
Get full text

GsMTx-4 venom toxin antagonizes biophysical modulation of metastatic traits in human osteosarcoma cells by Arianna Buglione, Giulia Alloisio, Chiara Ciaccio, David Becerril Rodriguez, Simone Dogali, Marco Luce, Stefano Marini, Antonio Cricenti, Magda Gioia

“…Thus, suggesting its potential as a promising therapeutic agent for targeting osteosarcoma metastasis…”
Get full text